Regulator orders Sun Pharma to shut Assam plant over eye-drop quality lapses; what you should know
Sun Pharmaceutical is in focus.
· Business Today Mkts
The action prevents Sun Pharma, India's biggest pharmaceutical company, from resuming ophthalmic drug production at the facility until regulators accept its compliance report.
The analysis
Against that, the stock is +0.9% on the day at ₹1,777.70, and has returned -11.2% over three months. It sits 11% below its 52-week high. The pharma & healthcare sector has moved -0.9% over the same period, so Sun Pharmaceutical is running 10.3 points behind its peers.
For Sun Pharmaceutical, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Market context
- In focus: Sun Pharmaceutical (SUNPHARMA), in Pharma & Healthcare.
- Over three months: Sun Pharmaceutical -11.2% against Pharma & Healthcare -0.9% (10.3 points behind).
- Trading well above normal today: Sun Pharmaceutical at 3.4 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Sun PharmaceuticalSUNPHARMA · Pharma & Healthcare | ₹1,777.70 | +0.9% | -2.1% | -11.2% | -11.2% | 3.4× | — |
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Sun Pharmaceutical
Prices as of 30 Oct 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Sun Pharma Q2 profit falls 36% as litigation costs hit earnings
Stocks To Watch Today: Dixon Tech, Syrma SGS, Sun Pharma, Wipro, Trent Among Others
Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%
Acutaas Chemicals among 5 stocks hitting 52-week highs; rallied up to 18% in a month